Alliance in Advanced Genomics for the development of Personalized Therapies in Navarre
The AGATA project is a research project formed by a multidisciplinary consortium that faces the challenge of demonstrating the value of applying genomics in the implementation of personalized medicine and its application to the diagnosis, prognosis, and development of new therapies for cancer, taking this development to clinical practice in Navarra.
AGATA is based on the application of Next-Generation Sequencing (NGS) techniques, a technology that allows to increase the accuracy in the diagnosis of cancer patients, improve their prognosis, and to optimize the monitoring of their response to treatment. The development of this technology is one of the essential pillars in the design of new personalized medicine strategies.
This consortium is made up of different agents from the biomedical and technological sector in Navarra, which are essential for the development of this research and its transfer to the patient. Specifically, two research centers (FIMA/CIMA and FMS/Navarrabiomed), two hospitals (Complejo Hospitalario de Navarra and Clínica Universidad de Navarra), a technological platform (CIMA LAB Diagnostics) and two Navarrese biotechnology companies (Recombina Biotech and Nasertic) participate in the consortium.
This research continues the work carried out in the DIANA project, another research project with which the researchers implemented and validated mass sequencing technologies available in Navarra for the genetic analysis of tumors and the design of their possible treatment.
The AGATA project is funded by the Government of Navarra within its 2020 call for strategic R&D projects.
Coordinator and partners
AGATA project participants
- FIMA through Cima Universidad de Navarra
- Clínica Universidad de Navarra
- Navarra Hospital Complex
- Miguel Servet Foundation through Navarrabiomed
- Recombina Biotech
Objectives of the AGATA project
Implementing personalized cancer medicine
To develop diagnostic and follow-up techniques
of patients by quantifying and characterizing tumor cells and circulating DNA.
To know the transcriptome of tumor cells
and its relationship with genomic alterations.
Innovate in single-cell analysis technologies
to improve diagnostic accuracy and design more effective treatments.
Apply NGS techniques for the prevention
and early identification of cancer.
To identify new targets
for the development of new therapeutic strategies.
AGATA Project participants
- María Manuela Peñas
- Leire García
- Cristina Perpiña
- Juana Prieto
- Gorka Lasheras
- Gonzalo Etayo
- Cristina Marzal
- Jorge Jiménez